Prediction: Novo Nordisk Will Soar Over the Next 5 Years. Here's 1 Reason Why.

Core Insights - The stock price of Novo Nordisk has significantly decreased after a strong performance in 2024, but it is expected to recover and grow further in the coming years [1] Industry Overview - The obesity rate in the U.S. has more than doubled from 1990 to 2022, rising from slightly over 21% to nearly 44% [2] - Globally, obesity affected over 1 billion people in 2022, leading to an expected surge in sales of weight loss drugs, which exceeded $30 billion worldwide for the first time in 2024 [3] - Morgan Stanley has revised its forecast for weight loss drug sales in 2030 from $77 billion to a range of $105 billion to $144 billion, indicating a potential threefold increase in less than a decade [4] Competitive Landscape - Novo Nordisk and Eli Lilly are the leading companies in the U.S. weight loss drug market, with Eli Lilly's Zepbound as a notable competitor [5] - The approval process for new medications in major markets like the U.S. and the EU is lengthy, giving established products like Wegovy an advantage [6] - Even if Novo Nordisk faces competition from Eli Lilly or new entrants, it is likely to maintain a significant market share in a rapidly growing industry [6]